Healthcare provider profile · identity verified

Mark A Scheible, MD

Family Practice · BLAINE, MN · NPI 1255342242

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	444	127
Atorvastatin Calcium	Atorvastatin Calcium	367	110
Metoprolol Succinate	Metoprolol Succinate	254	74
Metformin Hcl Er	Metformin Hcl	250	69
Omeprazole	Omeprazole	235	73
Lisinopril	Lisinopril	215	66
Levothyroxine Sodium	Levothyroxine Sodium	214	59
Tamsulosin Hcl	Tamsulosin Hcl	183	60
Amlodipine Besylate	Amlodipine Besylate	170	51
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	163	52
Losartan Potassium	Losartan Potassium	126	41
Escitalopram Oxalate	Escitalopram Oxalate	119	38
Glimepiride	Glimepiride	114	34
Prednisone	Prednisone	105	62
Finasteride	Finasteride	97	28
Allopurinol	Allopurinol	95	25
Pantoprazole Sodium	Pantoprazole Sodium	91	25
Bupropion Xl	Bupropion Hcl	85	23
Simvastatin	Simvastatin	79	23
Pioglitazone Hcl	Pioglitazone Hcl	75	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	70	20
Furosemide	Furosemide	68	23
Tizanidine Hcl	Tizanidine Hcl	64	13
Ozempic	Semaglutide	62	15
Trazodone Hcl	Trazodone Hcl	62	21
Sertraline Hcl	Sertraline Hcl	61	20
Metoprolol Tartrate	Metoprolol Tartrate	60	18
Hydrochlorothiazide	Hydrochlorothiazide	58	20
Celecoxib	Celecoxib	56	24
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	56	17
Albuterol Sulfate Hfa	Albuterol Sulfate	54	29
Zolpidem Tartrate	Zolpidem Tartrate	54	19
Tramadol Hcl	Tramadol Hcl	53	16
Clopidogrel	Clopidogrel Bisulfate	49	15
Gabapentin	Gabapentin	49	18
Warfarin Sodium	Warfarin Sodium	47	14
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	46	12
Metformin Hcl	Metformin Hcl	43	13
Duloxetine Hcl	Duloxetine Hcl	42	14
Trulicity	Dulaglutide	42	11
Pregabalin	Pregabalin	41	14
Atenolol	Atenolol	40	suppressed
Valsartan	Valsartan	40	12
Carvedilol	Carvedilol	39	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	39	suppressed
Eliquis	Apixaban	38	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	38	13
Montelukast Sodium	Montelukast Sodium	38	13
Fluticasone Propionate	Fluticasone Propionate	37	16
Glipizide Er	Glipizide	36	11
Ezetimibe	Ezetimibe	33	suppressed
Potassium Chloride	Potassium Chloride	32	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	30	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	30	19
Donepezil Hcl	Donepezil Hcl	29	suppressed
Nystatin	Nystatin	29	suppressed
Oxycodone Hcl	Oxycodone Hcl	29	11
Sucralfate	Sucralfate	29	suppressed
Alprazolam	Alprazolam	26	14
Azelastine Hcl	Azelastine Hcl	26	11
Lamotrigine	Lamotrigine	26	suppressed
Mirtazapine	Mirtazapine	26	11
Bumetanide	Bumetanide	25	suppressed
Propranolol Hcl Er	Propranolol Hcl	25	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	24	suppressed
Breo Ellipta	Fluticasone/Vilanterol	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Xarelto	Rivaroxaban	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Cephalexin	Cephalexin	22	22
Doxazosin Mesylate	Doxazosin Mesylate	22	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Meloxicam	Meloxicam	21	suppressed
Memantine Hcl	Memantine Hcl	21	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Fenofibrate	Fenofibrate	20	suppressed
Ondansetron Odt	Ondansetron	20	11
Synthroid	Levothyroxine Sodium	20	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	19	suppressed
Propranolol Hcl	Propranolol Hcl	19	suppressed
Alendronate Sodium	Alendronate Sodium	18	suppressed
Chlorthalidone	Chlorthalidone	18	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	12
Primidone	Primidone	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	13
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Clonazepam	Clonazepam	16	suppressed
Eszopiclone	Eszopiclone	16	suppressed
Famotidine	Famotidine	16	suppressed
Ipratropium Bromide	Ipratropium Bromide	16	suppressed
Loperamide	Loperamide Hcl	15	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Temazepam	Temazepam	15	suppressed
Incruse Ellipta	Umeclidinium Bromide	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Midodrine Hcl	Midodrine Hcl	14	suppressed
Oxycontin	Oxycodone Hcl	14	suppressed
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	12
Glipizide	Glipizide	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Aripiprazole	Aripiprazole	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Indomethacin	Indomethacin	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error